Circulating biomarkers in classical Hodgkin lymphoma

Wouter Johannes Plattel

doi:10.33612/diss.97631424

Circulating biomarkers in classical Hodgkin lymphoma

Wouter Johannes Plattel

Research output: Thesis › Thesis fully internal (DIV)

2412 Downloads (Pure)

Abstract

In classical Hodgkin lymphoma (cHL) there is an urgent need for biomarkers to determine prognosis or treatment response. In this thesis we summarized current knowledge on circulating biomarkers in cHL and studied a selection of these markers as treatment response or prognostic biomarkers. In the first part of this thesis we studied the application of Thymus and Activation Regulated Chemokine (TARC) as a biomarker for treatment response and compared TARC with sGal-1, sCD163 and sCD30 and interim FDG-PET imaging. We found that TARC at diagnosis correlates with metabolic tumor volume and that serial TARC measurements during and after treatment accurately reflect treatment response. In comparison to sGal-1, sCD163 and sCD30, TARC dynamics most accurately reflected treatment response. In addition, interim TARC had a higher positive predictive value for final treatment response compared to interim FDG-PET imaging. All together, we concluded that TARC is a cheap, non-invasive and highly accurate biomarker to determine treatment response in cHL patients.
In the second part of this thesis, we focused on microRNAs (miRNAs) as circulating biomarkers. We summarized the role of miRNAs in cHL and concluded that deregulation of miRNAs is a frequent event and an important factor in the pathobiology of cHL. Next, we summarized pre-analytical, analytical and post-analytical challenges in circulating miRNAs studies in general. Finally, we performed miRNA microarray profiling of serum of patients with cHL. Using this approach, we were unable to find circulating miRNAs with prognostic value in classical Hodgkin lymphoma.

Original language	English
Qualification	Doctor of Philosophy
Awarding Institution	University of Groningen
Supervisors/Advisors	van den Berg, Anke, Supervisor Kluin-Nelemans, Hanneke, Supervisor van Imhoff, Gustaaf, Co-supervisor Visser, Lydia, Co-supervisor
Award date	16-Oct-2019
Place of Publication	[Groningen]
Publisher	Rijksuniversiteit Groningen
Print ISBNs	978-94-034-1960-2
Electronic ISBNs	978-94-034-1959-6
DOIs	https://doi.org/10.33612/diss.97631424
Publication status	Published - 2019

Access to Document

10.33612/diss.97631424

Title and contentsFinal publisher's version, 560 KB
Chapter 1Final publisher's version, 1.43 MB
Chapter 2Final publisher's version, 690 KB
Chapter 3Final publisher's version, 800 KB
Chapter 4Final publisher's version, 1.1 MB
Chapter 5Final publisher's version, 1.47 MB
Chapter 6Final publisher's version, 678 KB
Chapter 7Final publisher's version, 1.07 MB
Chapter 8Final publisher's version, 667 KB
Chapter 9Final publisher's version, 995 KB
AppendicesFinal publisher's version, 551 KB
Complete thesisFinal publisher's version, 3.38 MB
PropositionsFinal publisher's version, 35.9 KB

Handle.net

Persistent link

Cite this

@phdthesis{e46f041b380d4b5b8c591bca5201a7dd,

title = "Circulating biomarkers in classical Hodgkin lymphoma",

abstract = "In classical Hodgkin lymphoma (cHL) there is an urgent need for biomarkers to determine prognosis or treatment response. In this thesis we summarized current knowledge on circulating biomarkers in cHL and studied a selection of these markers as treatment response or prognostic biomarkers. In the first part of this thesis we studied the application of Thymus and Activation Regulated Chemokine (TARC) as a biomarker for treatment response and compared TARC with sGal-1, sCD163 and sCD30 and interim FDG-PET imaging. We found that TARC at diagnosis correlates with metabolic tumor volume and that serial TARC measurements during and after treatment accurately reflect treatment response. In comparison to sGal-1, sCD163 and sCD30, TARC dynamics most accurately reflected treatment response. In addition, interim TARC had a higher positive predictive value for final treatment response compared to interim FDG-PET imaging. All together, we concluded that TARC is a cheap, non-invasive and highly accurate biomarker to determine treatment response in cHL patients.In the second part of this thesis, we focused on microRNAs (miRNAs) as circulating biomarkers. We summarized the role of miRNAs in cHL and concluded that deregulation of miRNAs is a frequent event and an important factor in the pathobiology of cHL. Next, we summarized pre-analytical, analytical and post-analytical challenges in circulating miRNAs studies in general. Finally, we performed miRNA microarray profiling of serum of patients with cHL. Using this approach, we were unable to find circulating miRNAs with prognostic value in classical Hodgkin lymphoma.",

author = "Plattel, {Wouter Johannes}",

year = "2019",

doi = "10.33612/diss.97631424",

language = "English",

isbn = "978-94-034-1960-2",

publisher = "Rijksuniversiteit Groningen",

school = "University of Groningen",

}

TY - BOOK

T1 - Circulating biomarkers in classical Hodgkin lymphoma

AU - Plattel, Wouter Johannes

PY - 2019

Y1 - 2019

N2 - In classical Hodgkin lymphoma (cHL) there is an urgent need for biomarkers to determine prognosis or treatment response. In this thesis we summarized current knowledge on circulating biomarkers in cHL and studied a selection of these markers as treatment response or prognostic biomarkers. In the first part of this thesis we studied the application of Thymus and Activation Regulated Chemokine (TARC) as a biomarker for treatment response and compared TARC with sGal-1, sCD163 and sCD30 and interim FDG-PET imaging. We found that TARC at diagnosis correlates with metabolic tumor volume and that serial TARC measurements during and after treatment accurately reflect treatment response. In comparison to sGal-1, sCD163 and sCD30, TARC dynamics most accurately reflected treatment response. In addition, interim TARC had a higher positive predictive value for final treatment response compared to interim FDG-PET imaging. All together, we concluded that TARC is a cheap, non-invasive and highly accurate biomarker to determine treatment response in cHL patients.In the second part of this thesis, we focused on microRNAs (miRNAs) as circulating biomarkers. We summarized the role of miRNAs in cHL and concluded that deregulation of miRNAs is a frequent event and an important factor in the pathobiology of cHL. Next, we summarized pre-analytical, analytical and post-analytical challenges in circulating miRNAs studies in general. Finally, we performed miRNA microarray profiling of serum of patients with cHL. Using this approach, we were unable to find circulating miRNAs with prognostic value in classical Hodgkin lymphoma.

AB - In classical Hodgkin lymphoma (cHL) there is an urgent need for biomarkers to determine prognosis or treatment response. In this thesis we summarized current knowledge on circulating biomarkers in cHL and studied a selection of these markers as treatment response or prognostic biomarkers. In the first part of this thesis we studied the application of Thymus and Activation Regulated Chemokine (TARC) as a biomarker for treatment response and compared TARC with sGal-1, sCD163 and sCD30 and interim FDG-PET imaging. We found that TARC at diagnosis correlates with metabolic tumor volume and that serial TARC measurements during and after treatment accurately reflect treatment response. In comparison to sGal-1, sCD163 and sCD30, TARC dynamics most accurately reflected treatment response. In addition, interim TARC had a higher positive predictive value for final treatment response compared to interim FDG-PET imaging. All together, we concluded that TARC is a cheap, non-invasive and highly accurate biomarker to determine treatment response in cHL patients.In the second part of this thesis, we focused on microRNAs (miRNAs) as circulating biomarkers. We summarized the role of miRNAs in cHL and concluded that deregulation of miRNAs is a frequent event and an important factor in the pathobiology of cHL. Next, we summarized pre-analytical, analytical and post-analytical challenges in circulating miRNAs studies in general. Finally, we performed miRNA microarray profiling of serum of patients with cHL. Using this approach, we were unable to find circulating miRNAs with prognostic value in classical Hodgkin lymphoma.

U2 - 10.33612/diss.97631424

DO - 10.33612/diss.97631424

M3 - Thesis fully internal (DIV)

SN - 978-94-034-1960-2

PB - Rijksuniversiteit Groningen

CY - [Groningen]

ER -

Circulating biomarkers in classical Hodgkin lymphoma

Abstract

Access to Document

Handle.net

Fingerprint

Cite this